Biopharma Companies – But Not PhRMA – Argue That Mifepristone Ruling ‘Radically Alters’ NDA Process

 
• By Brenda Sandburg
Mifepristone
Biopharma companies aska appeals court to stay mifepristone ruling against FDA • Source: Shutterstock

More from US FDA

More from Agency Leadership